Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry Pertinez

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
The AAPS Journal|November 22, 2014
Empirical and semi-mechanistic modelling of double-peaked pharmacokinetic profile phenomenon due to gastric emptyingKayode Ogungbenro, Henry Pertinez, Leon Aarons
Pharmaceutical Research|April 2, 2013
A physiologically based pharmacokinetic model for strontium exposure in ratHenry Pertinez, Marylore Chenel, Leon Aarons
Medrxiv : the Preprint Server for Health Sciences|January 14, 2021
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2Henry Pertinez, Rajith Kr Rajoli, Saye H Khoo, et al.
The Journal of Antimicrobial Chemotherapy|June 2, 2021
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2Henry Pertinez, Rajith K R Rajoli, Saye H Khoo, et al.
The Journal of Antimicrobial Chemotherapy|February 22, 2019
Bedaquiline kills persistent Mycobacterium tuberculosis with no disease relapse: an in vivo model of a potential cureYanmin Hu, Henry Pertinez, Yingjun Liu, et al.
Antimicrobial Agents and Chemotherapy|April 18, 2018
Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse ModelYingjun Liu, Henry Pertinez, Geraint R Davies, et al.
Pharmaceuticals (Basel, Switzerland)|January 8, 2025
Exploring the Feasibility of a Bracketing Approach Utilizing Modeling for Development of Long-Acting Injectables for Regulatory Approval-A Case Study Using LevonorgestrelSusan Cole, Henry Pertinez, Andrew S Butler, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 25, 2012
Progress curve mechanistic modeling approach for assessing time-dependent inhibition of CYP3A4Howard J Burt, Henry Pertinez, Carolina Säll, et al.
The Journal of Antimicrobial Chemotherapy|December 16, 2017
Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteriaYingjun Liu, Henry Pertinez, Fatima Ortega-Muro, et al.
Antimicrobial Agents and Chemotherapy|May 25, 2016
Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse ModelYanmin Hu, Henry Pertinez, Fatima Ortega-Muro, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
The AAPS Journal|November 22, 2014
Empirical and semi-mechanistic modelling of double-peaked pharmacokinetic profile phenomenon due to gastric emptyingKayode Ogungbenro, Henry Pertinez, Leon Aarons
Pharmaceutical Research|April 2, 2013
A physiologically based pharmacokinetic model for strontium exposure in ratHenry Pertinez, Marylore Chenel, Leon Aarons
Medrxiv : the Preprint Server for Health Sciences|January 14, 2021
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2Henry Pertinez, Rajith Kr Rajoli, Saye H Khoo, et al.
The Journal of Antimicrobial Chemotherapy|June 2, 2021
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2Henry Pertinez, Rajith K R Rajoli, Saye H Khoo, et al.
The Journal of Antimicrobial Chemotherapy|February 22, 2019
Bedaquiline kills persistent Mycobacterium tuberculosis with no disease relapse: an in vivo model of a potential cureYanmin Hu, Henry Pertinez, Yingjun Liu, et al.
Antimicrobial Agents and Chemotherapy|April 18, 2018
Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse ModelYingjun Liu, Henry Pertinez, Geraint R Davies, et al.
Pharmaceuticals (Basel, Switzerland)|January 8, 2025
Exploring the Feasibility of a Bracketing Approach Utilizing Modeling for Development of Long-Acting Injectables for Regulatory Approval-A Case Study Using LevonorgestrelSusan Cole, Henry Pertinez, Andrew S Butler, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 25, 2012
Progress curve mechanistic modeling approach for assessing time-dependent inhibition of CYP3A4Howard J Burt, Henry Pertinez, Carolina Säll, et al.
The Journal of Antimicrobial Chemotherapy|December 16, 2017
Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteriaYingjun Liu, Henry Pertinez, Fatima Ortega-Muro, et al.
Antimicrobial Agents and Chemotherapy|May 25, 2016
Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse ModelYanmin Hu, Henry Pertinez, Fatima Ortega-Muro, et al.
Pageof 5